Castration-resistant prostate cancer: mechanisms, targets, and treatment.
about
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Gene expression profiling analysis of castration-resistant prostate cancerThe hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.Prostate cancer metastatic to bone has higher expression of the calcium-sensing receptor (CaSR) than primary prostate cancerSelf-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyCurrent Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain.Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in MiceNES1/KLK10 gene represses proliferation, enhances apoptosis and down-regulates glucose metabolism of PC3 prostate cancer cells.Silencing CAPN2 Expression Inhibited Castration-Resistant Prostate Cancer Cells Proliferation and Invasion via AKT/mTOR Signal Pathway.Triptorelin in the management of prostate cancer.Optimal therapy sequencing in metastatic castration-resistant prostate cancer.RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development.A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells.Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles.Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cellsDown-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells.Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cellsOncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis.Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells.Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data.Patient preferences for treatments to delay bone metastases.Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.Isobavachalcone Induces ROS-Mediated Apoptosis Targeting Thioredoxin Reductase 1 in Human Prostate Cancer PC-3 Cells
P2860
Q33775723-19CB02C5-7F87-4E5C-867B-B80413C2C2BDQ34294888-645A7784-D144-4D9F-A8FE-AEA6D04507BEQ35014196-09DA66BB-EDAB-4799-92AD-ED12DAC7A2A6Q35214708-6F03DED0-D2EA-4CA1-9C1A-3E2C91E9EEDEQ35695097-865081F9-6026-42C2-AEF9-51CB8DA970FEQ35746834-3F3F94E4-1C86-428A-9893-BBC4A9BFD43CQ35890508-EBC7BCE6-F0D0-4AA2-BD15-65EC2E425553Q35901283-64342C69-0A4B-484E-BD69-02A80A9F609CQ36329646-B06C44BA-03A2-47F3-83BB-AA1B5176EB26Q37661199-42607B3B-CE0E-4B86-B0F5-46115115E13BQ38068495-F08694ED-1892-4379-98AB-127CC33CE19AQ38097373-5724B683-53ED-4D97-85D5-F6519FE322CAQ38161395-DEFEC4BC-D6E9-4109-B402-FBB209A9F3B5Q38194528-4385A8D1-EFE4-4A56-BBDE-C62E9C54DEC3Q38206962-4593F84B-0667-4FA3-B420-331868213650Q38434103-B4AA8B49-D2EF-4F63-AE79-65D9F754E87FQ38721352-0256704E-88A9-4BC0-9CDC-6E538A64F4E1Q38791188-9058AB7F-2294-4BD9-9E63-A6FF2789B2DBQ38815759-22FE8137-61EC-4204-B01E-CDF313024CFCQ38967167-41C92FFA-629D-4198-A89B-5D3BF4F37A24Q39038797-6B6305B4-B85F-467A-97A3-7AFAF806B5EDQ39097201-9388CA37-A076-4D4A-B2FC-E45F13EA555EQ39150333-C56C440F-D9E0-4573-9FB5-9EEFE058AD5CQ39198252-1FF41058-6447-426A-8EF2-3D1A99F77D16Q39206549-E9CD8C34-0C49-4A25-842A-C65F305CE5D1Q40721274-47406E6F-28D1-48F4-A3A9-168956547663Q42140492-BBB05CFA-56BD-4033-B21D-C2F7026CE984Q48151505-AF596FCC-8C1C-4C70-AFC1-67682B91F8C4Q49181813-5CA7CB32-C83A-453B-8183-048944EA2A2DQ53264477-098FD7F2-506D-419E-9E14-308E63B23C83Q54403954-42CD201D-C020-44EA-A0F8-2DAB6208A25DQ58558437-223BE38F-1DC0-4F68-875E-C9BF3FA9A641
P2860
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
@ast
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
@en
type
label
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
@ast
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
@en
prefLabel
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
@ast
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
@en
P2093
P2860
P356
P1433
P1476
Castration-resistant prostate cancer: mechanisms, targets, and treatment
@en
P2093
Daniela Macedo
Isabel Fernandes
Teresa Maria Santos Amaral
P2860
P304
P356
10.1155/2012/327253
P50
P577
2012-03-05T00:00:00Z